The pathophysiology of intratracheal LPS or BLM lung injury mice model after LPS-priming
The pathophysiology of intratracheal LPS or BLM lung injury mice model after LPS-priming
批准号:
22590854
负责人:
TSUSHIMA Kenji
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2010
资助国家:
日本
项目状态:
已结题
起止时间:
2010 至 2012
中文摘要
为探讨肺泡巨噬细胞(AM)在急性肺损伤(ALI)模型预激反应中的作用,用Cl2MDP-脂质体(去势预激AM)处理WT小鼠,第3天后IT,第5天非耗竭预激组小鼠的BAL蛋白和BAL细胞数较耗竭预激AM组减少。肺组织学显示非AM耗竭预充组第5天损伤几乎完全消失;AM耗竭预充组间质增厚和肺实变持续存在。流式细胞仪检测显示,Cl2MDP-脂质体处理组在0d时90%以上的AM被耗尽。耗竭预激AM组与非耗竭预激AM组相比,BAL肿瘤坏死因子-α在第1天降低,第5天升高,而BAL IL-10在第1天高于非耗竭预激AM组。与预充WT小鼠相比,IL-10缺失的小鼠未表现出预充可加速肺损伤的消退。这些研究表明,AM来源的IL-10参与了脂多糖诱导的ALI的加速分解。与启动相关的机制的定义可以为ALI潜在的新疗法提供重要的见解。
英文摘要
To examine potential roles for alveolar macrophages (AM) in the priming response in model of acute lung injury (ALI), primed WT mice were treated with Cl2MDP-liposome (depleted primed AM) on day -3 followed by IT. By day 5, the non-depleted primed group exhibited reduced bronchoalveolar lavage (BAL) protein and BAL cells compared to depleted primed AM group. Lung histology revealed nearly complete resolution of injury on day 5 in non-AM-depleted primed group; interstitial thickening and lung consolidation persisted in the AM-depleted primed group. Flow cytometry revealed thatat day 0 over 90% of AMs were depleted in the Cl2MDP-liposome treated group. BAL tumor necrosis factor-alpha was lower on day 1 and was higher on day 5 in depleted primed AM group compared to non-depleted primed AM group while BAL IL-10 was higher in non-depleted primed AM group on day 1 after LPS. In contrast to primed WT mice, IL-10-null mice did not exhibit accelerated resolution of lung injury with priming. These studies implicate AM-derived IL-10 in the accelerated resolution of ALI produced by LPS priming. Definition of mechanisms related to priming could provide important insights into potential new therapies for ALI..
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.rmed.2010.05.014
发表时间:
2010-11-01
期刊:
RESPIRATORY MEDICINE
影响因子:
4.3
作者:
[Tsushima, Kenji, Sone, Shusuke, Kubo, Keishi]
通讯作者:
Kubo, Keishi
シンポジウム ALI/ARDS 薬物療法の厳重と将来 抗凝固療法
研讨会 ALI/ARDS 药物治疗的严格性和未来 抗凝治疗
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[久米裕昭, 牧野 靖, 東田有智, 千田金吾, 津島健司]
通讯作者:
津島健司
Phase II trial of biweekly paclitaxel and gemcitabine as second-line chemotherapy for non-small cell lung cancer previsously treated with platinum-based chemotherapy.
双周紫杉醇和吉西他滨作为二线化疗用于先前接受铂类化疗的非小细胞肺癌的 II 期试验。
DOI:
--
发表时间:
2011
期刊:
Shinshu Med J
影响因子:
--
作者:
[Kobayashi T, Koizumi T, Yasuo M, Tsushima K, et al.]
通讯作者:
et al.
第3回セミナーALF/ARDS抗凝固療法
第三期ALF/ARDS抗凝治疗研讨会
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[田澤立之, 中田光, 津島健司]
通讯作者:
津島健司
第3回セミナー ALI/ARDS抗凝固療法
第三届ALI/ARDS抗凝治疗研讨会
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[Yamatoji M, et al, 津島健司]
通讯作者:
津島健司
共 19 条